Skip to content
value.today

Frequency Therapeutics, Inc.

🇺🇸 Woburn, Massachusetts, USABiotechnologyFounded 2014
Total raised
$94 M
2 rounds on record
Latest round
$62 M
Jul 2019
First round on record
Mar 2017
Today
Went public
See the company page

Frequency Therapeutics, Inc. is listed today as Korro Bio, Inc.: market value, financials and filings are on its company page.

Funding rounds

2 counted as startup funding, 1 other private sales on record. Open the number of investors for the round's details.

Funding rounds of Frequency Therapeutics, Inc.
MonthRaisedRaiseSizeInvestorsSoldFiling
Jul 2020$42 MPrivate placement after listing$10 to $50 million

Frequency Therapeutics, Inc.: Private sale, Jul 2020

Investors in this round

18 investors had bought by the notice of Jul 27, 2020: 18 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round. 10 investors are named for Frequency Therapeutics, Inc. as a whole in other filings: see Investors below.

What the notice says

Amount sold
$42 M of $42 M offered
Smallest investment taken
no minimum stated
What was sold
equity
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
$2,045,098
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Carl P. LeBel · Executive Officer
  • Christopher R. Loose · Executive Officer
  • Dana P. Hilt · Executive Officer
  • David L. Lucchino · Executive Officer, Director
  • Richard S. Mitrano · Executive Officer
  • Wendy S. Arnold · Executive Officer
  • Joel S. Marcus · Director
  • Marc A. Cohen · Director
  • Michael S. Huang · Director
  • Robert S. Langer · Director
  • Timothy J. Barberich · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

  • Cowen and Company, LLC (CRD 7616) · New York, New YorkSold in all US states

Signed by Michael D. Bookman, Deputy General Counsel. Source: SEC Form D, newest notice filed Jul 27, 2020. Read the notice at the SEC.

equitySEC
Jul 2019$62 MNo. 2$50 to $250 million

Frequency Therapeutics, Inc.: Raise no. 2, Jul 2019

Investors in this round

80 investors had bought by the notice of Jul 23, 2019: 80 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round. 10 investors are named for Frequency Therapeutics, Inc. as a whole in other filings: see Investors below.

What the notice says

Amount sold
$62 M of $62 M offered
Smallest investment taken
no minimum stated
What was sold
equity
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Carl S. Lebel · Executive Officer
  • Christopher R. Loose · Executive Officer
  • David Lucchino · Executive Officer, Director
  • Richard S. Mitrano · Executive Officer
  • Joel R. Marcus · Director
  • Marc R. Cohen · Director
  • Michael S. Huang · Director
  • Robert S. Langer · Director
  • Timothy R. Barberich · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Signed by David Lucchino, President. Source: SEC Form D, newest notice filed Jul 23, 2019. Read the notice at the SEC.

equitySEC
Mar 2017$32 MNo. 1$10 to $50 million

Frequency Therapeutics, Inc.: Raise no. 1, Mar 2017

Investors in this round

90 investors had bought by the notice of Apr 14, 2017: 90 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round. 10 investors are named for Frequency Therapeutics, Inc. as a whole in other filings: see Investors below.

What the notice says

Amount sold
$32 M of $32 M offered
Smallest investment taken
no minimum stated
What was sold
equity
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Christopher R. Loose · Executive Officer
  • David Lucchino · Executive Officer, Director
  • Marc R. Cohen · Director
  • Marc R. Kozin · Director
  • Robert R. Langer · Director
  • Timothy R. Barberich · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Remarks in the notice

  • On the amounts: “Certain of the securities sold resulted from the conversion of outstanding notes (including interest).”

Signed by David Lucchino, President. Source: SEC Form D, newest notice filed Apr 14, 2017. Read the notice at the SEC.

equitySEC

Source: SEC Form D. Each row is one private sale of securities with the running total of its newest notice. The form does not name the series or the investors; rounds are numbered in the order they were filed. A round's details show what its notice does say: accredited and other investors, the smallest investment taken, the exemption claimed, fees, the people named and the brokers paid to sell it.

How it makes money#

What its filings and its own website say, sentence by sentence, each with its source.

  • Frequency Therapeutics, Inc. chose not to state its revenue in its newest notice of a funding round (Jul 2020).

    SEC Form D · Jul 2020

  • The industry group it chose in its notices: Biotechnology.

    SEC Form D · Jul 2020

That is all the official record says: Frequency Therapeutics, Inc. has not published its revenue in a filing we can read, and no other official source covers it. Revenue figures come from crowdfunding filings (SEC Form C) and from annual reports once a company is listed.

Products and services#

No products or services of Frequency Therapeutics, Inc. are on record.

Investors#

10 named in official filings. Open an investor to see everything it has backed.

Investors in Frequency Therapeutics, Inc.
InvestorKindAmountRoundRoleSource
Alexandria Venture Investments, LLCVenture capitalnot statednot statedHeld Series A and B preferred stock, 10% owner (Form 3, 2019)SEC Form 3
Christopher R. LoosePersonnot statednot statedHeld Series A preferred stock (Form 3, 2019)SEC Form 3
David L. LucchinoPersonnot statednot statedHeld Series A and B preferred stock, director (Form 3, 2019)SEC Form 3
Deerfield Management Company, L.P.Fund or asset managernot statednot statedHeld Series C preferred stock, 10% owner (Form 3, 2019)SEC Form 3
Deerfield Mgmt IV, L.P.Fund or asset managernot statednot statedHeld Series C preferred stock, 10% owner (Form 3, 2019)SEC Form 3
Deerfield Mgmt L.P.Fund or asset managernot statednot statedHeld Series C preferred stock, 10% owner (Form 3, 2019)SEC Form 3
Deerfield Private Design Fund IV, L.P.Fund or asset managernot statednot statedHeld Series C preferred stock, 10% owner (Form 3, 2019)SEC Form 3
Deerfield Special Situations Fund, L.P.Fund or asset managernot statednot statedHeld Series C preferred stock, 10% owner (Form 3, 2019)SEC Form 3
Joel S. MarcusPersonnot statednot statedHeld Series A and B preferred stock, 10% owner, director (Form 3, 2019)SEC Form 3
Timothy J. BarberichPersonnot statednot statedHeld Series A and C preferred stock, director (Form 3, 2019)SEC Form 3

Source: SEC Form 3 statements, SEC Form N-PORT fund reports, Wikidata, value.today research. Names come from filings that do name holders: the preferred stock each holder had when the company registered its shares (Form 3), private shares in US mutual funds' portfolio reports (N-PORT), and Wikidata. None ties a name to one funding round, so this list is per company, and it is not complete: the 2 rounds above had up to 90 investors.

Largest shareholders today

Institutions holding Korro Bio, Inc. shares, as of Sep 30, 2026.

Source: SEC Form 13F holdings reports · as of Sep 30, 2026. Value held and share of the company. All holders are on the company page.

Executives and directors

As the company named them in its notices. Directors of a funded startup are often partners of its investors.

People named by Frequency Therapeutics, Inc.
NameRoleNamed in
Carl P. LeBelExecutive officerJul 2020
Christopher R. LooseExecutive officerJul 2020
Dana P. HiltExecutive officerJul 2020
David L. LucchinoExecutive officerJul 2020
Richard S. MitranoExecutive officerJul 2020
Wendy S. ArnoldExecutive officerJul 2020
Carl S. LebelExecutive officerJul 2019
David LucchinoExecutive officerJul 2019
David L. LucchinoDirectorJul 2020
Joel S. MarcusDirectorJul 2020
Marc A. CohenDirectorJul 2020
Michael S. HuangDirectorJul 2020
Robert S. LangerDirectorJul 2020
Timothy J. BarberichDirectorJul 2020
David LucchinoDirectorJul 2019
Joel R. MarcusDirectorJul 2019
Marc R. CohenDirectorJul 2019
Timothy R. BarberichDirectorJul 2019
Marc R. KozinDirectorApr 2017
Robert R. LangerDirectorApr 2017

Went public since 2019. Its SEC number is that of a company listed on a stock exchange.